Figure S4. (A)The potential signaling pathway contributed to imatinib resistance in GIST. The green boxes and the solid arrows represented the previously reported signaling pathways related with imatinib resistance; the orange boxes and the dotted arrows represented the potential signaling pathway contributed to imatinib resistance in GIST. (B) Validated genes (9 genes) in protein-protein interaction network. (TIF 319Â kb
Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 50% of t...
Figure S1. Genome-wide synthetic lethal screens with RAS1(V19) and RAS2(V19) identify overlapping se...
Figure S1A. GIST882 cells stably expressing ShNC or ShKDM4D were transfected with HIF1β plasmids or...
Figure S1. Optical microscopic images of GIST-T1 cells treated with imatinib (40, 60 and 80Â Îźg/mL)...
Figure S3. Optical microscopic images of GIST-T1 cells with individual gene/miRNA knockouts and imat...
Table S5. Detailed information of GO analysis for the selected 20 genes. (DOCX 13Â kb
Table S4. Candidate genesmiRNAs with sgRNA sequence, total reads and diversity. (DOCX 13Â kb
Figure S2. PCR amplification of sgRNA region for deep-sequencing analysis. (A) Successful transfecti...
Figure S3. Pathway enrichment by RNA-Seq. Dot plots showing the enrichment results of KEGG pathway a...
Abstract Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in ima...
Figure S3. The mRNA expression and the fold change of the hub genes. (A) the mRNA expression of hub ...
Figure S1. Heat maps of differentially expressed genes associated with imatinib resistance (we selec...
Figure S2. GPR124, ALK and KMT2D proteins converge on HSP90AA1. An evaluation of the potential role ...
Table S1. 20 hub genes with siRNA synthesizers and sequence [34â52]. (DOCX 19 kb
Figure S1. Schematic of drug-inducible sgRNA expression lentiviral vectors. Figure S2. Nucleotide se...
Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 50% of t...
Figure S1. Genome-wide synthetic lethal screens with RAS1(V19) and RAS2(V19) identify overlapping se...
Figure S1A. GIST882 cells stably expressing ShNC or ShKDM4D were transfected with HIF1β plasmids or...
Figure S1. Optical microscopic images of GIST-T1 cells treated with imatinib (40, 60 and 80Â Îźg/mL)...
Figure S3. Optical microscopic images of GIST-T1 cells with individual gene/miRNA knockouts and imat...
Table S5. Detailed information of GO analysis for the selected 20 genes. (DOCX 13Â kb
Table S4. Candidate genesmiRNAs with sgRNA sequence, total reads and diversity. (DOCX 13Â kb
Figure S2. PCR amplification of sgRNA region for deep-sequencing analysis. (A) Successful transfecti...
Figure S3. Pathway enrichment by RNA-Seq. Dot plots showing the enrichment results of KEGG pathway a...
Abstract Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in ima...
Figure S3. The mRNA expression and the fold change of the hub genes. (A) the mRNA expression of hub ...
Figure S1. Heat maps of differentially expressed genes associated with imatinib resistance (we selec...
Figure S2. GPR124, ALK and KMT2D proteins converge on HSP90AA1. An evaluation of the potential role ...
Table S1. 20 hub genes with siRNA synthesizers and sequence [34â52]. (DOCX 19 kb
Figure S1. Schematic of drug-inducible sgRNA expression lentiviral vectors. Figure S2. Nucleotide se...
Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 50% of t...
Figure S1. Genome-wide synthetic lethal screens with RAS1(V19) and RAS2(V19) identify overlapping se...
Figure S1A. GIST882 cells stably expressing ShNC or ShKDM4D were transfected with HIF1β plasmids or...